Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hepatitis C

  Free Subscription


Articles published in Am J Gastroenterol

Retrieve available abstracts of 25 articles:
HTML format



Single Articles


    February 2024
  1. BUI H, Kumar NG, Singal AG, Boparai J, et al
    Implementation of a hepatocellular carcinoma surveillance program in a community-based integrated health system in patients with hepatitis C cirrhosis.
    Am J Gastroenterol. 2024 Feb 9. doi: 10.14309/ajg.0000000000002704.
    PubMed     Abstract available


    December 2023
  2. HU TH, Luh DL, Tsao YY, Lin TY, et al
    Utilizing the Diabetes Care System for A County-wide Hepatitis C Elimination: An Integrated Community-based Shared Care Model in Taiwan.
    Am J Gastroenterol. 2023 Dec 12. doi: 10.14309/ajg.0000000000002624.
    PubMed     Abstract available


  3. BARRITT AS 4TH, Barnhart H, Gu J, Dellinger A, et al
    When Is Suspected Drug-Induced Liver Injury (DILI) Not DILI? An Analysis of Unlikely Cases From the Drug-Induced Liver Injury Network.
    Am J Gastroenterol. 2023;118:2301-2304.
    PubMed     Abstract available


    July 2023
  4. BARNHILL MS, Vargas HE
    Immune-Checkpoint Inhibitors in the Hepatitis C-Infected Patient: To Use or Not to Use?
    Am J Gastroenterol. 2023 Jul 10. doi: 10.14309/ajg.0000000000002352.
    PubMed    


    June 2023
  5. YIBIRIN M, Mustafayev K, Hosry J, Pundhir P, et al
    Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors.
    Am J Gastroenterol. 2023 Jun 13. doi: 10.14309/ajg.0000000000002361.
    PubMed     Abstract available


    November 2022
  6. KRAMER JR, Cao Y, Li L, Smith D, et al
    Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection.
    Am J Gastroenterol. 2022;117:1834-1844.
    PubMed     Abstract available


  7. SHOREIBAH M
    Continuing Medical Education Questions: November 2022.
    Am J Gastroenterol. 2022;117:1742.
    PubMed     Abstract available


    September 2022
  8. VELOZ MFG, Han K, Oakes K, Robertson D, et al
    Results of a model of delivering hepatitis C care in a homeless metropolitan population in England.
    Am J Gastroenterol. 2022 Sep 30. pii: 00000434-990000000-00534.
    PubMed     Abstract available


    June 2022
  9. INNES H, Hamill V, McDonald SA, Hayes PC, et al
    Comparing predicted probability of hepatocellular carcinoma in cirrhosis patients to the general population: an opportunity to improve risk communication?
    Am J Gastroenterol. 2022 Jun 24. pii: 00000434-990000000-00428.
    PubMed     Abstract available


  10. CALVARUSO V, Celsam C, D'Ambrosio R, Simone F, et al
    RESIST-HCV criteria to monitor progression of low-risk esophageal varices in patients with compensated cirrhosis after HCV eradication. The SIMPLE study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices.
    Am J Gastroenterol. 2022 Jun 17. pii: 00000434-990000000-00413.
    PubMed     Abstract available


    May 2022
  11. AMPUERO J, Carmona I, Sousa F, Rosales JM, et al
    Correction to: A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure.
    Am J Gastroenterol. 2022;117:819.
    PubMed    


    January 2022
  12. FAYED A, Hegazy MT, Biard L, Vieira M, et al
    Relapse of HCV-Cryoglobulinemic Vasculitis Following Sustained Viral Response after Interferon-free Direct-Acting Antivirals.
    Am J Gastroenterol. 2022 Jan 29. pii: 00000434-990000000-00234.
    PubMed     Abstract available


    October 2021
  13. LI J, Le MH, Barakat MT, Cheung RC, et al
    The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016.
    Am J Gastroenterol. 2021;116:2068-2078.
    PubMed     Abstract available


    September 2021
  14. AMPUERO J, Carmona I, Sousa F, Rosales JM, et al
    A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure.
    Am J Gastroenterol. 2021 Sep 9. pii: 00000434-900000000-98663.
    PubMed     Abstract available


  15. CHUANG WL, Hu TH, Buggisch P, Moreno C, et al
    Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease.
    Am J Gastroenterol. 2021;116:1924-1928.
    PubMed     Abstract available


  16. ZAMOR PJ, Brown A, Dylla DE, Dillon JF, et al
    High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
    Am J Gastroenterol. 2021;116:1896-1904.
    PubMed     Abstract available


    August 2021
  17. KONSTANTELOS N, Shakeri A, McCormack D, Feld JJ, et al
    Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada.
    Am J Gastroenterol. 2021;116:1738-1740.
    PubMed     Abstract available


    June 2021
  18. RINALDI L, Messina V, Di Marco V, Iovinella V, et al
    Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience.
    Am J Gastroenterol. 2021;116:1248-1255.
    PubMed     Abstract available


    April 2021
  19. SHARMA S, Saraya A
    Avoiding Beta Blockers in Patients of Hepatitis C Virus-Related Compensated Cirrhosis With Clinically Significant Portal Hypertension After Cure With Antivirals: Are We There Yet?
    Am J Gastroenterol. 2021 Apr 9. pii: 00000434-900000000-98829.
    PubMed    


    March 2021
  20. ROGAL S, Youk A, Agbalajobi O, Zhang H, et al
    Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
    Am J Gastroenterol. 2021 Mar 30. pii: 00000434-900000000-98834.
    PubMed     Abstract available


    February 2021
  21. TOSETTI G, Degasperi E, Farina E, D'Ambrosio R, et al
    Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Beta-Blocker Therapy.
    Am J Gastroenterol. 2021 Feb 18. pii: 00000434-900000000-98881.
    PubMed     Abstract available


    December 2020
  22. LI J, Gordon SC, Zhou Y, Boscarino JA, et al
    Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C.
    Am J Gastroenterol. 2020;Publish Ahead of Print.
    PubMed     Abstract available


  23. DESAI N, Rich NE, Jain MK, Blackwell JM, et al
    Randomized Clinical Trial of Inreach With or Without Mailed Outreach to Promote Hepatitis C Screening in a Difficult-to-Reach Patient Population.
    Am J Gastroenterol. 2020;Publish Ahead of Print.
    PubMed     Abstract available


    October 2020
  24. SINN DH, Kang D, Guallar E, Chang Y, et al
    Alcohol Intake and Mortality in Patients With Chronic Viral Hepatitis: A Nationwide Cohort Study.
    Am J Gastroenterol. 2020 Oct 8. doi: 10.14309/ajg.0000000000000966.
    PubMed     Abstract available


  25. SHARMA S, Agarwal S, Gunjan D, Kaushal K, et al
    Deciding Among Noninvasive Tools for Predicting Varices Needing Treatment in Chronic Liver Disease: An Analysis of Asian Cohort.
    Am J Gastroenterol. 2020;115:1650-1656.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.